Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 50Lymphoma 30Lung Neoplasms 29Breast Neoplasms 28Prostatic Neoplasms 25Multiple Myeloma 25Melanoma 21Lymphoma, Non-Hodgkin 20Carcinoma, Non-Small-Cell Lung 20Ovarian Neoplasms 19Leukemia, Myeloid, Acute 19Glioma 18Pancreatic Neoplasms 17Neoplasm Metastasis 17Urinary Bladder Neoplasms 15Hematologic Neoplasms 15Colorectal Neoplasms 15Carcinoma, Renal Cell 15Sarcoma 14Burkitt Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neuroblastoma 13Colonic Neoplasms 12Carcinoma 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Myelodysplastic Syndromes 11Leukemia, Lymphocytic, Chronic, B-Cell 11Ependymoma 11Brain Neoplasms 11

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Castrate Sensitive Prostate Cancer × 30 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡